Organogenesis Inc. is a global leader in advanced wound care innovation and technologies. Organogenesis’ product portfolio includes FDA-approved Apligraf® and Dermagraft®, the best-in-class products for bio-active wound healing, and FDA-cleared PuraPly Antimicrobial™, which advances wound management for a wide variety of wound types.
Product Categories
Pharmaceuticals
- Pharmaceuticals
Synthetic and Biosynthetic
- Synthetic and Biosynthetic
Wound Care
- Cellular
- Skin Care
- Tissue-based